An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases

Wiener Medizinische Wochenschrift

Volumn 160, Issue 17-18, 2010, Pages 458-463

  Maldonado Gonzales, Eduardo ^a   Pietschmann, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bone metastases; Denosumab; Multiple myeloma; Osteoporosis; RANKL; Rheumatoid arthritis

Indexed keywords

ALENDRONIC ACID; CORTICOSTEROID; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETIDRONIC ACID; IBANDRONIC ACID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

BONE DENSITY; BONE METASTASIS; CELLULITIS; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; FLATULENCE; FRAGILITY FRACTURE; HUMAN; HYPERTENSION; IDIOPATHIC OSTEOPOROSIS; MULTIPLE MYELOMA; OSTEOPOROSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE NEOPLASMS; BONE RESORPTION; CLINICAL TRIALS AS TOPIC; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; OSTEOCLASTS; OSTEOPOROSIS; RANK LIGAND; TREATMENT OUTCOME;

EID: 78149406898     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-010-0812-3     Document Type: Review

References (44)

1. DL Lacey E Timms HL Tan, et al. 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 2 165 176 1:CAS:528:DyaK1cXivVyhtrg%3D 10.1016/S0092-8674(00)81569-X 9568710 (Pubitemid 28180851)
2. H Yasuda N Shima N Nakagawa, et al. 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 95 7 3597 3602 1:CAS:528:DyaK1cXitlKjsLY%3D 10.1073/pnas.95.7.3597 9520411 (Pubitemid 28173173)
3. TL Burgess Y Qian S Kaufman, et al. 1999 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts J Cell Biol 145 3 527 538 1:CAS:528:DyaK1MXivFKntr8%3D 10.1083/jcb.145.3.527 10225954 (Pubitemid 29215717)
4. PJ Bekker D Holloway A Nakanishi, et al. 2001 The effect of a single dose of osteoprotegerin in postmenopausal women J Bone Miner Res 16 2 348 360 1:CAS:528:DC%2BD3MXptlOquw%3D%3D 10.1359/jbmr.2001.16.2.348 11204435
5. N Bucay I Sarosi CR Dunstan, et al. 1998 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 12 9 1260 1268 1:CAS:528:DyaK1cXjtVejsrs%3D 10.1101/gad.12.9.1260 9573043
6. M Rauner W Sipos P Pietschmann 2007 Osteoimmunology Int Arch Allergy Immunol 143 1 31 48 10.1159/000098223 17191007 (Pubitemid 46625234)
7. YY Kong U Feige I Sarosi, et al. 1999 Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 402 6759 304 309 1:CAS:528:DyaK1MXnvFShsLg%3D 10.1038/46303 10580503
8. E Romas NA Sims DK Hards, et al. 2002 Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis Am J Pathol 161 4 1419 1427 1:CAS:528:DC%2BD38Xotl2jsbg%3D 12368214
9. DR Haynes TN Crotti M Loric, et al. 2001 Osteoprotegerin and receptor activator of nuclear factor kappa B ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint Rheumatology (Oxford) 40 6 623 630 1:CAS:528:DC%2BD3MXlsFSiu70%3D 10.1093/rheumatology/40.6.623
10. J Body 2003 Effectiveness and cost of bisphosphonate therapy in tumor bone disease Cancer 97 3 Suppl 859 865 10.1002/cncr.11139 12548587
11. RJ Thomas TA Guise JJ Yin, et al. 1999 Breast cancer cells interact with osteoblasts to support osteoclast formation Endocrinology 140 10 4451 4458 1:CAS:528:DyaK1MXmtFGru78%3D 10.1210/en.140.10.4451 10499498
12. AT Mancino VS Klimberg M Yamamoto, et al. 2001 Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells J Surg Res 100 1 18 24 1:CAS:528:DC%2BD3MXmtVOnsbo%3D 10.1006/jsre.2001.6204 11516200 (Pubitemid 32807701)
13. S Kitazawa R Kitazawa 2002 RANK ligand is a prerequisite for cancer-associated osteolytic lesions J Pathol 198 2 228 236 1:CAS:528: DC%2BD3sXivV2js74%3D 10.1002/path.1199 12237883 (Pubitemid 35243881)
14. JM Brown E Corey ZD Lee, et al. 2001 Osteoprotegerin and rank ligand expression in prostate cancer Urology 57 4 611 616 1:STN:280: DC%2BD3M3ms1WrsQ%3D%3D 10.1016/S0090-4295(00)01122-5 11306358
15. J Zhang J Dai Y Qi, et al. 2001 Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone J Clin Invest 107 10 1235 1244 1:CAS:528:DC%2BD3MXjsl2ntr0%3D 10.1172/JCI11685 11375413
16. JJ Body P Greipp RE Coleman, et al. 2003 A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases Cancer 97 3 Suppl 887 892 10.1002/cncr.11138 12548591
17. O Sezer U Heider I Zavrski, et al. 2003 RANK ligand and osteoprotegerin in myeloma bone disease Blood 101 6 2094 2098 1:CAS:528:DC%2BD3sXit1egsrc%3D 10.1182/blood-2002-09-2684 12424190 (Pubitemid 36302042)
18. WJ Boyle WS Simonet DL Lacey 2003 Osteoclast differentiation and activation Nature 423 6937 337 342 1:CAS:528:DC%2BD3sXjs1ynu7g%3D 10.1038/nature01658 12748652 (Pubitemid 40852708)
19. MR McClung EM Lewiecki SB Cohen, et al. 2006 AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 821 831 1:CAS:528:DC%2BD28Xhsl2gs7o%3D 10.1056/NEJMoa044459 16495394 (Pubitemid 43290920)
20. GK Ellis HG Bone R Chlebowski, et al. 2008 Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 30 4875 4882 1:CAS:528:DC%2BD1cXhtlGitrzO 10.1200/JCO.2008.16.3832 18725648
21. W Sipos P Pietschmann M Rauner, et al. 2009 Pathophysiology of osteoporosis Wien Med Wochenschr 159 9-10 230 234 10.1007/s10354-009-0647-y 19484205
22. C Schiller R Gruber K Redlich, et al. 1997 17Beta-estradiol antagonizes effects of 1alpha,25-dihydroxyvitamin D3 on interleukin-6 production and osteoclast-like cell formation in mouse bone marrow primary cultures Endocrinology 138 11 4567 4571 1:CAS:528:DyaK2sXmslGku7k%3D 10.1210/en.138.11. 4567 9348179 (Pubitemid 27460888)
23. SR Cummings LJ Melton 2002 Epidemiology and outcomes of osteoporotic fractures Lancet 359 9319 761 1767 10.1016/S0140-6736(02)08657-9 (Pubitemid 34614532)
24. HP Dimai P Pietschmann H Resch, et al. 2009 Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose - Update 2009 Wien Med Wochenschr 159 Suppl 122 1 34 10.1007/s10354-009-0656-x
25. PJ Bekker DL Holloway AS Rasmussen, et al. 2004 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 20 12 2275 2282
26. EM Lewiecki PD Miller MR McClung, et al. 2007 AMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD J Bone Miner Res 22 12 1832 1841 1:CAS:528:DC%2BD2sXhsVyjtrjF 10.1359/jbmr.070809 17708711 (Pubitemid 351229299)
27. PD Miller MA Bolognese EM Lewiecki, et al. 2008 Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial Bone 43 2 222 229 1:CAS:528:DC%2BD1cXosVOitrk%3D 10.1016/j.bone.2008.04.007 18539106
28. JP Brown RL Prince C Deal, et al. 2009 Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial J Bone Miner Res 24 1 153 161 1:CAS:528:DC%2BD1MXht1yrtbc%3D 10.1359/jbmr.0809010 18767928
29. SR Cummings J San Martin MR McClung, et al. 2009 FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 8 756 765 1:CAS:528:DC%2BD1MXhtVWls7nF 10.1056/NEJMoa0809493 19671655
30. MR Smith B Egerdie NH Toriz R Feldman TLJ Tammela FJ Saad J Heracek M Szwedowski C Ke A Kupic BZ Leder C Goessl for the Denosumab HALT Prostate Cancer Study Group 2009 Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 8 745 755 1:CAS:528:DC%2BD1MXhtVWls7rF 10.1056/NEJMoa0809003 19671656
31. Lispky PE. Rheumatoid arthritis. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine, 16th edn. McGraw-Hill Companies Inc., Medical Publishing Division, New York, 2005
32. N Saidenberg-Kermanac'h N Bessis M Cohen-Solal, et al. 2002 Osteoprotegerin and inflammation Eur Cytokine Netw 13 2 144 153 12101070
33. SB Cohen RK Dore NE Lane, et al. 2008 Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial Arthritis Rheum 58 5 1299 1309 1:CAS:528:DC%2BD1cXms1ehu70%3D 10.1002/art.23417 18438830 (Pubitemid 351705919)
34. Dore RK, Cohen SB, Lane NE, Palmer WR, Shergy W, Zhou L, Wang H, Tsuji W, Newmark R. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis, 2009.[Epub ahead of print]
35. E Terpos E Efstathiou D Christoulas M Roussou E Katodritou MA Dimopoulos 2009 RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases Expert Opin Biol Ther 9 4 465 479 1:CAS:528:DC%2BD1MXktFCjsrg%3D 10.1517/14712590902845610 19344283
36. JJ Body T Facon RE Coleman, et al. 2006 A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer Clin Cancer Res 12 4 1221 1228 1:CAS:528:DC%2BD28XhsFaltLg%3D 10.1158/1078-0432.CCR-05-1933 16489077 (Pubitemid 43342512)
37. K Yonemori Y Fujiwara H Minami, et al. 2008 Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases Cancer Sci 99 6 1237 1242 1:CAS:528: DC%2BD1cXnsVOrsb4%3D 10.1111/j.1349-7006.2008.00803.x 18429961 (Pubitemid 351676637)
38. K Fizazi L Bosserman G Gao, et al. 2009 Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial J Urol 182 2 509 515 1:CAS:528:DC%2BD1MXpsFGmu7Y%3D 10.1016/j.juro.2009.04.023 19524963
39. A Lipton GG Steger J Figueroa C Alvarado P Solal-Celigny JJ Body R de Boer R Berardi P Gascon KS Tonkin R Coleman AH Paterson MC Peterson M Fan A Kinsey S Jun 2007 Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases J Clin Oncol 25 28 4431 4437 1:CAS:528:DC%2BD2sXht1ertrjP 10.1200/JCO.2007.11.8604 17785705 (Pubitemid 350013849)
40. A Lipton GG Steger J Figueroa, et al. 2008 Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy Clin Cancer Res 14 20 6690 6696 1:CAS:528: DC%2BD1cXht1Kgur3M 10.1158/1078-0432.CCR-07-5234 18927312
41. K Fizazi A Lipton X Mariette, et al. 2009 Randomized phase II trial of denosumab in patients wirh bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates J Clin Oncol 27 10 1564 1571 1:CAS:528:DC%2BD1MXltVOhtr0%3D 10.1200/JCO.2008.19.2146 19237632
42. GK Ellis HG Bone R Chlebowski D Paul S Spadafora M Fan D Kim 2009 Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study Breast Cancer Res Treat 118 1 81 87 1:CAS:528:DC%2BD1MXht1GmtbfI 10.1007/s10549-009-0352-y 19308727
43. K Vanderkerken E De Leenheer C Shipman, et al. 2003 Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma Cancer Res 63 2 287 289 1:CAS:528:DC%2BD3sXnt1Kltg%3D%3D 12543775
44. R Vij N Horvath A Spencer K Taylor S Vadhan-Raj R Vescio J Smith Y Qian H Yeh S Jun 2009 An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma Am J Hematol 84 10 650 656 1:CAS:528:DC%2BD1MXhtlyqsLnP 10.1002/ajh.21509 19714603